Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation

Transplantation

Volumn 91, Issue 3, 2011, Pages 271-278

  Teramura, Yuji ^a   Iwata, Hiroo ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Bioartificial pancreas; Intraportal transplantation; Islets; Poly(ethylene glycol) lipid (PEG lipid); Urokinase

Indexed keywords

DISTEARYLGLYCEROLPHOSPHATIDYLETHANOLAMINE; DNA; GLUCOSE; INSULIN; MACROGOL; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DNA HYBRIDIZATION; ENZYME IMMOBILIZATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GRAFT RECIPIENT; GRAFT SURVIVAL; HYDROPHOBICITY; INSTANT BLOOD MEDIATED INFLAMMATORY REACTION; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; SURFACE PROPERTY; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; GRAFT SURVIVAL; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; PLASMINOGEN; POLYETHYLENE GLYCOLS; STREPTOZOCIN; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79951494036     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182034fa4     Document Type: Article

References (28)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710.
3. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039.
4. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755.
5. van der Windt DJ, Bottino R, Casu A, et al. Rapid loss of intraportally transplanted islets: An overview of pathophysiology and preventive strategies. Xenotransplantation 2007; 14: 288.
6. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: Possible application of the thrombin inhibitor mel-agatran in clinical islet transplantation. Diabetes 2002; 51: 1779.
7. Johansson H, Goto M, Dufrane D, et al. Low molecular weight dextran sulfate: A strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006; 6: 305.
8. Nilsson B, Korsgren O, Lambris JD, et al. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 2010; 31: 32.
9. Contreras JL, Xie D, Mays J, et al. A novel approach to xenotransplan-tation combining surface engineering and genetic modification of isolated adult porcine islets. Surgery 2004; 136: 537.
10. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56: 2008.
11. Teramura Y, Iwata H. Surface modification of islets with PEG-lipid for improvement of graft survival in intraportal transplantation. Transplantation 2009; 88: 624.
12. Teramura Y, Iwata H. Bioartificial pancreas microencapsulation and con-formal coating of islet of Langerhans. Adv Drug Deliv Rev 2010; 62: 827.
13. Teramura Y, Iwata H. Cell surface modification with polymers for bio-medical studies. Soft Matter 2010; 6: 1081.
14. Teramura Y, Iwata H. Islet encapsulation with living cells for improvement of biocompatibility. Biomaterials 2009; 30: 2270.
15. Teramura Y, Kaneda Y, Totani T, et al. Behavior of synthetic polymers immobilized on cell membrane. Biomaterials 2008; 29: 1345.
16. TeramuraY,KanedaY,Iwata H.Islet-encapsulationinultra-thin layer-by-layer membranes of poly(vinyl alcohol) anchored to poly(ethylene glycol)-lipids in the cell membrane. Biomaterials 2007; 28: 4818.
17. Miura S, Teramura Y, Iwata H. Encapsulation of islets with ultra-thin poly-ion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane. Biomaterials 2006; 27: 5828.
18. Totani T, Teramura Y, Iwata H. Immobilization of urokinase to islet surface by amphiphilic poly (vinyl alcohol) carrying alkyl side chains. Biomaterials 2008; 29: 2878.
19. Teramura Y, Iwata H. Islets surface modification prevents blood-mediated inflammatory responses. Bioconjugate Chem 2008; 19: 1389.
20. Teramura Y, Chen H, Kawamoto T, et al. Control of cell attachment through polyDNA hybridization. Biomaterials 2010; 31: 2229.
21. Teramura Y, Minh LM, Kawamoto T, et al. Microencapsulation of islets with living cells using polyDNA-PEG-lipid conjugate. Bioconju-gate Chem 2010; 21: 792.
22. Inui Y, Teramura Y, Iwata H. Retention dynamics of amphiphilic polymers, PEG-lipids and PVA-alkyl, on the cell surface. ACS Appl Mater Interfaces 2010; 2: 1514.
23. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjugate Chem 1995; 6: 150.
24. Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipatic poly(eth-ylene glycol)s effectively prolong the circulation time of liposome. FEBS Lett 1990; 268: 235.
25. Bradley AJ, Devine DV, Ansell SM, et al. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 1998; 357: 185.
26. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 2002; 18: 37.
27. Arima Y, Toda M, Iwata H. Complement activation on surfaces modified with ethylene glycol units. Biomaterials 2008; 29: 551.
28. Evans MG, Warnock GL, Rajotte RV. Comparison of sites for transplantation of canine pancreatic microfragments. Diabetes Res 1989; 10: 35.